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Inhibiting PAD2 enhances the anti-tumor
effect of docetaxel in tamoxifen-resistant
breast cancer cells
Fujun Li1,2†, Lixia Miao1†, Teng Xue1†, Hao Qin1, Santanu Mondal3, Paul R. Thompson3, Scott A. Coonrod4,
Xiaoqiu Liu5* and Xuesen Zhang1*
Abstract
Background: Tamoxifen resistance presents a huge clinical challenge for breast cancer patients. An understanding
of the mechanisms of tamoxifen resistance can guide development of efficient therapies to prevent drug resistance.
Methods: We first tested whether peptidylarginine deiminase 2 (PAD2) may be involved in tamoxifen-resistance in
breast cancer cells. The effect of depleting or inhibiting PAD2 in tamoxifen-resistant MCF-7 (MCF7/TamR) cells was
evaluated both in vitro and in vivo. We then investigated the potential of Cl-amidine, a PAD inhibitor, to be used in
combination with tamoxifen or docetaxel, and further explored the mechanism of the synergistic and effective
drug regimen of PADs inhibitor and docetaxel on tamoxifen-resistant breast cancer cells.
Results: We report that PAD2 is dramatically upregulated in tamoxifen-resistant breast cancer. Depletion of PAD2 in
MCF7/TamR cells facilitated the sensitivity of MCF7/TamR cells to tamoxifen. Moreover, miRNA-125b-5p negatively
regulated PAD2 expression in MCF7/TamR cells, therefore overexpression of miR-125b-5p also increased the cell
sensitivity to tamoxifen. Furthermore, inhibiting PAD2 with Cl-amidine not only partially restored the sensitivity of
MCF7/TamR cells to tamoxifen, but also more efficiently enhanced the efficacy of docetaxel on MCF7/TamR cells
with lower doses of Cl-amidine and docetaxel both in vivo and in vivo. We then showed that combination
treatment with Cl-amidine and docetaxel enhanced p53 nuclear accumulation, which synergistically induced cell
cycle arrest and apoptosis. Meanwhile, p53 activation in the combination treatment also accelerated autophagy
processes by synergistically decreasing the activation of Akt/mTOR signaling, thus enhancing the inhibition of
proliferation.
Conclusion: Our results suggest that PAD2 functions as an important new biomarker for tamoxifen-resistant breast
cancers and that inhibiting PAD2 combined with docetaxel may offer a new approach to treatment of tamoxifen-
resistant breast cancers.
Keywords: Breast cancer, Tamoxifen-resistance, PAD2, Docetaxel
Background
Despite major advances in the development of antineo-
plastic agents, breast cancer remains as one of the most
prevalent malignant tumors and the first leading causes
of cancer morbidity and mortality in women worldwide
[1]. About 70% of breast cancers are estrogen receptor
(ER) positive. Tamoxifen, as one of the most prescribed
ER antagonists for first line adjuvant endocrine therapy,
has significant efficacy for ER-positive breast cancer, and
has been shown to substantially reduce recurrence and
mortality rate in ER-positive breast cancer patients [2].
Unfortunately, with 5 years of tamoxifen therapy, most
initially responsive patients experience a recurrence, and
the tumors are eventually resistant to tamoxifen [3, 4].
Therefore, the search for the mechanisms responsible
for endocrine resistance and effective treatment
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therapies for these breast cancers continues, which has
increased the popularity of combined therapies of two or
more cancer drugs [5].
A recent study showed that tamoxifen-resistant breast
cancer cells are resistant to DNA-damaging chemother-
apies, including cisplatin and adriamycin, but not to pac-
litaxel, suggesting that taxane-based chemotherapy may
be superior to DNA-damaging drugs when choosing
chemotherapy for tamoxifen-resistant breast cancer pa-
tients [6]. Docetaxel (formerly called taxotere) is a
second-generation taxane which is widely used in cancer
therapy, either as a monotherapy or as a combination
therapy across a variety of tumor types [7]. Currently,
docetaxel is still the first-line chemotherapy in breast
cancer and constitutes one of the most effective classes
of chemotherapeutics for prolonged survival in advanced
disease [8, 9]. Clinical studies also showed that combin-
ation of docetaxel with other cancer drugs yields good
results [5]. However, cumulative systemic toxicity after
prolonged and high-dose therapy was found to be asso-
ciated with safety issues among clinical trial patients in-
cluding hematological issues, asthenia, cutaneous
reactions, and neurosensory reactions [5, 10]. Clearly, it
is of high clinical significance to enhance the efficacy of
docetaxel using lower doses in a less toxic manner and
to reduce its side effects. Therefore, therapeutic strat-
egies that can either increase the effects of chemothera-
peutics or decrease the dosage are urgently needed for
the treatment of tamoxifen-resistant breast cancers.
Peptidylarginine deiminases (PADs) are a family of cal-
cium dependent enzymes that convert arginine into cit-
rulline in substrate proteins. Accumulating studies on
the PADs have gathered increased attention due to their
emerging roles in various human and animal cancers
[11, 12]. For example, we recently demonstrated that
PAD1 was upregulated in triple negative breast cancer
and regulated cancer cell metastasis by targeting MEK1
in ERK signaling pathway [13]. Other studies showed
that PAD2 and PAD4 were detected in a wide range of
human malignant cancers and suggested a link with can-
cer progression [11, 14–18]. During the transition from
benign mammary epithelium to malignant breast carcin-
omas, PAD2 expression was shown to be dramatically
upregulated [17]. A recent study also showed that PAD2
targets RNA polymerase II to facilitate gene expression
and cell proliferation in breast cancer cells [19]. In line
with these observations, PAD2 overexpression in breast
cancer and other cancers correlates with poor prognosis
[20–22]. Given the upregulated expression level of
PAD2 in breast cancers, depletion or inhibiting PAD2
should decrease tumor growth. In fact, McElwee and
colleagues demonstrated that a pan-PAD inhibitor, Cl-
amidine, strongly suppressed breast cancer cell growth
by altering the expression of both cell cycle and tumor
promoting genes [17]. Meanwhile, Wang and colleagues
developed a novel PAD inhibitor, YW3–56, also inhibits
cancerous growth by perturbing autophagy [23]. These
studies suggest that overexpression of PAD2 plays a piv-
otal role in regulating tumor progression, which may
open the possibility that specific inhibition of PAD2 ac-
tivity may represent a suitable drug target for new breast
cancer therapies.
However, nothing is known about whether PAD2 is in-
volved in endocrine resistance in breast cancers. Our
goal here was to formally test this hypothesis and then
investigate the effects of PAD2 inhibition in combination
with tamoxifen or docetaxel in cell culture, and preclin-
ical in vivo models of breast cancer. Our study is antici-
pated to provide a novel therapeutic approach to
improve clinical practice in treatment of tamoxifen-
resistant breast cancer with enhanced drug efficacy and
reduced side effects.
Methods
Cell culture
Tamoxifen-sensitive (TamS) and resistant (TamR) MCF-
7 cells were a gift from Dr. Joshua LaBaer at Biodesign
Institute. HEK293 and TamS cells were grown in Dul-
becco’s Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and 1% Penicillin
Streptomycin. TamR cells were grown in the same
media supplemented with 1 μM tamoxifen (Sigma-Al-
drich, USA). All cells were maintained at 37 °C in a hu-
midified 5% CO2 atmosphere. PAD2-depleted TamR/
MCF-7 cells were generated by transduction with Mis-
sion Lentiviral Transduction Particles containing a short
hairpin RNA (shRNA) construct targeting the human
PAD2 coding sequence (Sigma SHCLND-NM_007365).
In the control group, cells were transduced with a non-
targeting shRNA lentiviral construct (Sigma SHC002V).
Cells were selected by medium containing 1 μg/mL
puromycin (Sigma-Aldrich). For generating miR-125b-
5p overexpression TamR/MCF7 cells, retroviral particles
containing genomic DNA fragment (hg38_wgRna_hsa-
mir-125b-1 range = chr11:122099595–122,100,001)
cloned into pQXCIP construct were generated to infect
TamR/MCF7 cells. In the control group, TamR/MCF7
cells were transduced with an empty pQXCIP construct.
Cells were selected by medium containing 1 μg/mL
puromycin (Sigma-Aldrich). Where indicated, Cl-
amidine or docetaxel (Sigma-Aldrich) was diluted in cell
culture medium at the indicated concentration.
Cell proliferation assay and colony formation assay
Cells were seeded into 96-well plates (5000 cells/well),
incubated overnight and then treated with or without
Tamoxifen for 1, 2, 3, 4 and 5 days. 10 μL of cell count-
ing kit-8 (CCK-8) reagent (Yeasen, Shanghai, China) was
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added to each well, and plates were incubated for 4 h at
37 °C in accordance with the CCK-8 kit protocol. Op-
tical density (OD) values were measured at 450 nm using
a plate reader (Thermo Scientific Multiskan GO,
Finland). For colony formation assay, a single-cell sus-
pension was seeded into 6-well plates and grown for 4
days in the presence of 7 μM tamoxifen, fixed with 4%
paraformaldehyde, and stained with crystal violet for
subsequent colony counting analysis.
Apoptosis evaluation by flow cytometry and TUNEL
assays
Apoptotic cells were detected using the Annexin V-
fluorescein isothiocyanate (FITC) Apoptosis Detection Kit
(Yeasen, Shanghai, China). Briefly, following treatment of
cells, cells were washed and then cell pellets were re-
suspended in ice-cold binding buffer. Subsequently, 5 μL
Annexin V-FITC solution and 5 μL dissolved propidium
iodide (PI) were added to the cell suspension. After gentle
mixing, samples were incubated for 10min in the dark at
room temperature. A FACScan flow cytometer was ap-
plied to quantify cellular apoptosis. For terminal deoxynu-
cleotidyltransferase mediated dUTP-biotin nick end
labeling (TUNEL), cells were grown on glass slides in 12-
well plates, followed by fixation with 4% paraformalde-
hyde. TUNEL staining was performed with a TUNEL
Apoptosis Detection Kit (FITC) (Yeasen, Shanghai, China)
according to the manufacturer’s instructions. Following
TUNEL staining, cells were washed and then blocked with
4% bovine serum albumin for 5 min at room temperature.
Nuclei were visualized by DNA staining with Hoechst
stain (1 μg/mL). The images were captured using a Carl
Zeiss (Germany). TUNEL positive signal was counted
from randomly selected fields.
Quantitative real-time PCR
Total RNA was extracted using TRIzol (Invitrogen).
RNA quality and quantity were quantified with Nano-
drop 2000 spectrophotometer (Thermo Scientific). 500
ng total RNA was reversely transcribed into cDNA using
SuperScript™ III Reverse Transcriptase (Invitrogen).
Quantitative real-time PCR was performed using the
Power SYBR Green PCR Master Mix (Applied Biosys-
tems) with gene-specific primers. The primers used were
summarized in Additional file 2: Table S1. The relative
fold expressions were calculated using relative standard
curve method (2−ΔΔCt). For the analysis of cell apoptosis,
cell cycle and autophagy gene expression, cDNA was an-
alyzed using human Qiagen RT2 Profiler PCR Cell
Apoptosis Array (PAHS-012Z), Cell Cycle Array (PAHS-
020Z), and Autophagy Array (PAHS-084Z), separately.
Data were normalized using multiple housekeeping
genes and analyzed by comparing 2−ΔΔCt of the normal-
ized sample.
Western blot analysis
Radioimmunoprecipitation assay (RIPA) buffer contain-
ing protease inhibitors was used to extract total proteins,
and the lysates were boiled for 5 min before subjected to
10% SDS-PAGE. The proteins were then transferred to
PVDF membranes. The membranes were blocked and
incubated with the following primary antibodies over-
night at 4 °C: PAD1, PAD4 (Sigma-Aldrich); PAD2 (Pro-
teintech); Bcl-2, Bak, Bad, LC3B, GSK3β, caspase 3,
cleaved caspase 3, p-Rps-6, Rps-6, p-Akt, Akt (Cell Sig-
naling Technology, USA), p53 (Bioworld Technology,
China), and PAD3, GAPDH (Santa Cruz Biotechnology,
USA). The membranes were washed and then incubated
with HRP-conjugated secondary antibodies. The signals
were visualized using an Enhanced Chemiluminescence
Detection Kit (Pierce Biotechnology, USA).
Immunofluorescence staining
Cells were grown on glass slides in 12-well plates, then
fixed with 4% paraformaldehyde and permeabilized with
0.1% Triton X-100. After blocking, cells were incubated
with primary antibodies against LC3B. Then Fluor 555-
conjugated secondary antibody (Invitrogen) was employed
to detect fluorescence. The nuclei were stained with DAPI
(Vector Laboratories, Cambridgeshire, UK). Representa-
tive images were collected with LSM 510 laser scanning
confocal microscope (Carl Zeiss).
Nuclear and cytoplasmic extract preparations
Cells were washed twice with cold PBS and then lysed in
cold cell lysis buffer (1M Tris-HCl, pH = 7.9; 1M KCl,
10% NP40, 1x proteinase inhibitors) for 60 min on ice.
The lysates were then centrifuged and supernatants were
collected as cytoplasmic fraction. The pellets were
washed and then lysed in cold lysis buffer (1M Tris-
HCl, pH = 7.9; 0.5 M EDTA, 10%SDS, 1x proteinase in-
hibitors). The supernatants were collected as nuclear
fraction.
Immunoprecipitation assay
Flag-tagged PAD2 in pcDNA3.1(+) and HA-tagged-Ub
were transfected into HEK293 cells using FuGENE 6
(Roche). Cells were collected and lysed 40 h post trans-
fection and the whole cell lysates were immunoprecipi-
tated with anti-p53 antibody. Immunoprecipitates were
then washed and analyzed by western blot using anti-
HA antibody (Bioworld Technology, China). GAPDH
was used as a control as indicated.
Xenograft tumor model in nude mice
Female BALB/c nude mice (6-week-old) were purchased
from the Shanghai Laboratory Animal Center (Chinese
Academy of Sciences, Shanghai, China) and maintained
in a special pathogen-free environment. All procedures
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were reviewed and approved by the Institutional Animal
Care and Use Committee of Nanjing Medical University.
Cells (1 × 10^7) were injected subcutaneously into the
left upper flank of mice. Tumor diameters are measured
with digital calipers, and the tumor volume in mm3 was
calculated by the following formula: Volume = 0.5 x
(Width)2 x Length (n = 3). Alternatively, the tumor
weight was recorded (n = 3). For the experiment examin-
ing the effect of PAD2 inhibitor and docetaxel on tumor
growth, TamR/MCF-7 cells were injected subcutane-
ously into 24 female nude mice. The tumors were grown
for 2 weeks. Mice were randomly assigned into 4 groups
(n = 6) and administered intra-peritoneal injections of ei-
ther Cl-amidine (20 mg/kg/day) alone, docetaxel (10 mg/
kg/day) alone, or a combination of Cl-amidine and doce-
taxel every 3 days. Treatment continued for 3 weeks and
the mice were then sacrificed under anesthesia. The
tumor weight was recorded. PBS was used as injection
control.
Statistical analysis
All experiments were independently repeated at least
three times. Data are presented as mean ± SD. Statistical
evaluation for data analysis was determined by Student’s
t-test with *indicating means significantly different (P <
0.05) from control.
Results
PAD2 expression is highly upregulated in tamoxifen-
resistant breast cancer, and depletion of PAD2 facilitates
the sensitivity of MCF7/TamR cells to tamoxifen
To determine the clinical significance of PAD2 in
tamoxifen-resistant breast tumors, we first examined
PAD2 mRNA level in clinical tumor tissue microarray
during tamoxifen therapy using the publicly GEO data-
set GDS806/11785 (https://www.ncbi.nlm.nih.gov/geo-
profiles) [24]. As shown in Fig. 1a, PAD2 transcript
levels were elevated in breast tumor tissues from breast
cancer recurrence group compared to those patients
with disease free (tamoxifen sensitive) during tamoxifen
therapy, though P value was more than 0.05 (P = 0.0528).
Further analysis of PAD2 expression in tamoxifen-
resistant breast cancer cell line MCF7 (MCF7/TamR)
subclones confirmed that PAD2 was significantly (P =
9.39 × 10− 13) upregulated compared to the tamoxifen-
sensitive controls (MCF7/TamS) (Fig. 1b). Notably,
PAD2 transcript was more highly expressed in MCF7/
TamS cells compared to the other PADs family mem-
bers (Fig. 1c), and only PAD2 was significantly upregu-
lated in TamR/MCF7 cell (Fig. 1c and d). These results
indicate that elevated PAD2 levels, but not other PADs,
are associated with tamoxifen resistance in breast
cancer.
To further explore the role of PAD2 in the process of
tamoxifen resistance, we then stably depleted PAD2 in
TamR/MCF7 cells via a lentivirus-based approach. The
knockdown efficiency of PAD2 was checked via western
blot analysis (Fig. 1e). We then evaluated the effect of
PAD2 depletion on viability of TamR/MCF7 cells using
a CCK-8 assay. Results showed that, in the absence of
tamoxifen, depletion of PAD2 did not affect cell growth,
compared to the control cells (Fig. 1f). However, in the
presence of 2–7 μM tamoxifen, PAD2-knockdown
TamR/MCF7 cells showed a significant time-dependent
inhibition of cell proliferation (Fig. 1g and h). We also
confirmed the in vitro phenotype of TamR/MCF7 cells
under tamoxifen treatment in xenograft mouse model.
The PAD2-knockdown or the control TamR/MCF7 cells
were inoculated into the nude mice, separately. Two
weeks later, both cell lines were able to generate similar
size tumors. The mice from both groups were then ad-
ministrated with 3 mg/kg/day tamoxifen for additional
19 days. The mice bearing PAD2 knockdown cells exhib-
ited significantly smaller tumors than the mice with
shRNA control cells under tamoxifen treatment (Fig. 1i).
These results suggest that PAD2 depletion partially re-
stores the sensitivity of TamR/MCF7 cells to tamoxifen,
and also raised a possibility that inhibiting PAD2 might
help reverse tamoxifen resistance.
MiR-125b-5p negatively regulates PAD2 expression in
MCF7/TamR cells, and overexpression of miR-125b-5p
increases the sensitivity of MCF7/TamR cells to tamoxifen
The molecular mechanism underlying PAD2 upregulation
in tamoxifen resistance is completely unknown. A recent
study demonstrated that miR-125a-5p could target the 3′-
untranslated region (UTR) of PAD2 to negatively regulate
PAD2 expression in the process of liver metastasis of colo-
rectal cancer [25]. To identify upstream regulators of
PAD2 in MCF7/TamR cells, we first performed a bioinfor-
matics analysis using Bibiserv2 (https://bibiserv.cebitec.
uni-bielefeld.de) and found that PAD2 contains a putative
binding site for miR-125b-5p (Fig. 2a), which is another
miR-125 family member that has been reported to be
downregulated in breast cancers [26–28]. To validate this
prediction, the wild-type (WT) or mutated (Mut) 3’UTR
sequences of PAD2 were cloned into pGL3 luciferase re-
porter vector and co-transfected with miR-125b-5p
mimics or mimics controls (NC) into 293 T cells. The fol-
lowing luciferase reporter assay showed that miR-125b-5p
mimics significantly inhibited luciferase activity of the
WT-PAD2–3’UTR but not that of mutant (Fig. 2a), indi-
cating the authentic binding between miR-125b-5p and
PAD2–3’UTR. Moreover, our observation showing that
miR-125b-5p transcript was dramatically downregulated
in TamR/MCF7 cells (Fig. 2b) may be a causal mechanism
for explaining the increased PAD2 expression in TamR/
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MCF7 cells. To further test this hypothesis, we stably
overexpressed miR-125b-5p in TamR/MCF7 cells (Fig. 2c)
and found that PAD2 expression was inhibited in miR-
125b-5p overexpressed TamR/MCF7 cells (Fig. 2d). Again,
we did not observe a significant difference in cell growth
when miR-125b-5p was overexpressed, relative to the con-
trol cells (Fig. 2e). However, in the presence of 7 μM tam-
oxifen, miR-125b-5p significantly inhibited cell
proliferation and colony formation abilities of TamR/
MCF7 cells (Fig. 2f and g). Notably, tumor xenograft
mouse model also confirmed that miR-125b-5p overex-
pression would partially resensitize TamR/MCF7 cells to
tamoxifen (Fig. 2h). These results suggested that decreased
miR-152b-5p in TamR/MCF7 cells could upregulate
PAD2 expression during tamoxifen resistance in breast
cancers.
Fig. 1 PAD2 expression is highly upregulated in tamoxifen-resistant breast cancer, and depletion of PAD2 facilitates the sensitivity of MCF7/TamR
cells to tamoxifen. a Analysis of PAD2 mRNA levels in clinical tumor tissue microarray during tamoxifen therapy using the publicly GEO dataset GDS806/
11785. b Endogenous PAD2 mRNA levels in tamoxifen-resistant breast cancer cell line MCF7 (MCF7/TamR) were compared to tamoxifen-sensitive controls
(MCF7/TamS). GAPDH served as controls. c, d Endogenous PAD1–4 mRNA and protein levels in MCF7/TamR cells were determined by qRT-PCR (c) and
Western Blot (d). GAPDH served as loading control. e Stable PAD2 knockdown efficiency was confirmed by qRT-PCR and immunoblot. GAPDH served as
loading control. f MCF7/TamR cell proliferation was not affected upon PAD2 depletion by CCK8 assay, compared to the empty vector (shCon) control cells.
g Cell proliferation was inhibited in PAD2 knockdown MCF7/TamR cells by CCK8 assay, in the presence of 7 μM tamoxifen, compared to the empty vector
(shCon) control cells. h 7 μM tamoxifen treatment on TamR/MCF7 cells showed a time-dependent inhibition of cell proliferation. *P< 0.05. i The mice
bearing PAD2 knockdown cells exhibited smaller tumors than the mice with shRNA control cells post tamoxifen treatment (n= 3/group). The volume of
tumors at indicated time after cell implantation was quantified, and the average volume was plotted. *P< 0.05
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Fig. 2 MiR-125b-5p down-regulates PAD2 by directly targeting its 3’UTR and overexpression of miR-125b-5p increases the sensitivity of MCF7/
TamR cells to tamoxifen. a The PAD2 3’UTR contains the binding seed sequences of miR125b-5p according to online bioinformatics analysis
using Bibiserv2. Mutations of the 3′-UTR of PAD2 was used to create the mutant luciferase reporter construct. The WT and Mut-PAD2 3’UTR were
separately cloned into the pGL3 luciferase reporter vector, and luciferase reporter assay showed that the activity of WT-PAD2 3’UTR, but not the
mutant, was repressed by miR125b-5p overexpression. *P < 0.05. b qRT-PCR analysis showing that the endogenous miR125b-5p mRNA level was
downregulated in MCF7/TamR cells compared to that in MCF7/TamS cells. ***P < 0.001. c qRT-PCR analysis confirming that miR125b-5p was
stably overexpressed in MCF7/TamR cells. d PAD2 protein expression was downregulated by western blotting in miR125b-5p overexpressed
MCF7/TamR cells. e Cell proliferation was not affected upon in miR125b-5p overexpressed MCF7/TamR cells by CCK8 assay, compared to the
empty vector (EV Control). f Cell proliferation was inhibited in miR125b-5p overexpressed MCF7/TamR cells, in the presence of 7 μM tamoxifen,
compared to the empty vector control cells. g 7 μM tamoxifen treatment on miR125b-5p overexpressed MCF7/TamR cells showing that miR125b-
5p overexpression decreased colony formation. The data were presented as the mean ± SD from three independent experiments (left panel).
*P < 0.05. h The mice bearing miR125b-5p overexpressed MCF7/TamR cells exhibited smaller tumors than the mice with Empty vector control
cells post tamoxifen treatment (n = 3/group). The volume of tumors at indicated time after cell implantation was quantified, and the average
volume was plotted. *P < 0.05
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Inhibiting PAD2 combined with docetaxel synergistically
inhibited MCF7/TamR cells proliferation
Given that decreased PAD2 expression resensitizes
MCF7/TamR cells to tamoxifen, we determined whether
inhibiting PAD2 would have the same effect. To test this
hypothesis, we first treated cells with a PAD inhibitor,
Cl-amidine, which elicits strong cytotoxic effects on
breast cancer cells while having no observable effect on
non-cancerous lines [17, 29, 30]. For these experiments,
MCF7/TamR cells were incubated with increasing doses
of Cl-amidine for 48 h and then evaluated for cell viabil-
ity using the CCK8 assay. Cell viability was not signifi-
cantly affected until the concentration of Cl-amidine
reached 200 μM (Fig. 3a). Given the high concentration
of Cl-amidine in the cell culture media, we next treated
MCF7/TamR cells with 50 μM Cl-amidine. Results
showed that 50 μM Cl-amidine treatment alone did not
affect cell viability, however, 50 μM of Cl-amidine
combined with 5 μM tamoxifen significantly inhibited
MCF7/TamR cell growth by ~ 2-fold (Fig. 3b). These re-
sults not only confirmed our hypothesis that depletion
or inhibiting PAD2 will partially restore the sensitivity of
MCF7/TamR cells to tamoxifen, but also suggested that
PAD2 is a good therapeutic candidate for tamoxifen re-
sistant breast cancers.
It has been reported that combined therapies of either
docetaxel or tamoxifen with other cancer drugs have
yielded good results in clinical trials [5, 31]. A more re-
cent study also showed that tamoxifen-resistant MCF7
cells are sensitive to paclitaxel, while other major che-
motherapeutic drugs used in breast cancer, including
cisplatin or adriamycin, are not [6]. As PAD2 appears to
be a good therapeutic target for tamoxifen resistance, we
determined whether inhibiting PAD2 enhances the effi-
cacy of docetaxel on MCF7/TamR cells. To test this pos-
sibility, we first examined the cytotoxicity of docetaxel
Fig. 3 Inhibiting PAD2 re-sensitizes MCF7/TamR cells to docetaxel. a MCF7/TamR cells were treated with cl-amidine at the indicated
concentration for 4 days. CCK8 assay showing that 200 μM cl-amidine started to inhibit MCF7/TamR cell proliferation (***P < 0.001). b MCF7/TamR
cells were treated with cl-amidine at the indicated concentration for 4 days. CCK8 assay showing that 50 μM cl-amidine combined with 5 μM
tamoxifen significantly inhibited MCF7/TamR cell growth (*P < 0.05). c MCF7/TamR cells were treated with docetaxel at the indicated concentration for
4 days. CCK8 assay showing that at least 80 μM of docetaxel decreased MCF7/TamR cell viability (*P < 0.05). d MCF7/TamR cells were treated with
0.1 μM combined with different concentration of docetaxel for 4 days. CCK8 assay showing that at least 0.1 μM docetaxel and 25 μM cl-amidine
combination significantly decreased MCF7/TamR cell viability (***P < 0.001). e MCF7/TamR cells were treated with 0.1 μM docetaxel and 25 μMcl-
amidine for 1, 2, 3, 4, and 5 days. CCK8 assay showing that this combination completely inhibited MCF7/TamR cell viability (***P < 0.001)
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on our MCF7/TamR cells and found that 80 μM doce-
taxel significantly decreases cell viability (Fig. 3c). Next,
docetaxel showed a synergistic effect with Cl-amidine,
occurring at a low dose of 0.1 μM docetaxel (Fig. 3d). Of
note, this drug regimen even decreased the concentra-
tion of Cl-amidine to as low as 25 μM, compared to
50 μM Cl-amidine in combination with tamoxifen. We
then used 25 μM Cl-amidine combined with 0.1 μM do-
cetaxel for all future experiments, based on the com-
pletely inhibiting effect on viability of MCF7/TamR cells
after 5-days of treatment (Fig. 3e). Therefore, inhibiting
PAD2 not only resensitized MCF7/TamR cells to tam-
oxifen, but also greatly enhanced the efficacy of
docetaxel.
Cl-amidine combined with docetaxel synergistically
induces apoptosis, cell cycle arrest, and autophagy in
MCF7/TamR cells
Induction of cell death and cell cycle arrest are consid-
ered to be the main mechanisms for drug-dependent in-
hibition of cell growth [32]. The observed effect of Cl-
amidine combined with docetaxel on cell viability sug-
gested that the treatment might affect cell death. To
follow up on the underlying mechanism of this effect,
we first performed flow cytometric analysis to evaluate
apoptosis. As assessed by Annexin-V staining, apoptosis
was observed after exposure of MCF7/TamR cells to ei-
ther docetaxel or Cl-amidine for 4 days, while the com-
bination treatment with Cl-amidine and docetaxel
significantly accelerated the apoptotic rate as compared
to each individual treatment (Fig. 4a). Meanwhile, acti-
vation of caspases 3, downregulation of anti-apoptotic
protein Bcl-2, and upregulation of pro-apoptotic pro-
teins Bak and Bad in the combined treatment group
confirmed the induction of apoptosis in MCF7/TamR
cells (Fig. 4b). Further, cell cycle analysis with propi-
dium iodide (PI) staining of DNA showed that Cl-
amidine combined with docetaxel exhibited a much
stronger cell cycle arrest in the G2/M phase compared
to docetaxel or Cl-amidine alone (Fig. 4c and d), which
could lead to mitotic arrest and cell growth inhibition.
Autophagy can also promote cell death [33]. Thus, we
tested whether the combination treatment was able to
induce autophagy in MCF7/TamR cells. Using the
microtubule-associated protein light chain 3B (LC3B) as
a marker of autophagosomes, we observed that LC3B
Fig. 4 Cl-amidine combined with docetaxel synergistically induces cell apoptosis, cell cycle arrest, and autophagy in MCF7/TamR cells. a Flow cytometric
analysis of 0.1 μM docetaxel and 25 μMcl-amidine combincation accelerated apoptosis of the MCF7/TamR cells compared to either individual treatment. b
Western blot analysis of the activation of caspase 3, Bcl-2, Bak, and Bad in MCF7/TamR cells treated with 0.1 μM docetaxel and 25 μMcl-amidine. GAPDH
was used as an internal control. c,d Flow cytometric analysis of 0.1 μM docetaxel and 25 μMcl-amidine combination induced cell cycle arrest in the G2/M
phase compared to docetaxel or cl-amidine alone. The relative quantification was shown in (d). e Immunofluorescence staining for LC3B showing 0.1 μM
docetaxel and 25 μMcl-amidine combination induced large punctate structures in MCF7/TamR cells (white arrow). Nuclei were stained with DAPI. Scale
bar, 50 μm. fWestern blot analysis of the LC3B protein greatly accumulated under the combined treatment. GAPDH served as loading control
Li et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:414 Page 8 of 15
staining was not detected in control or docetaxel-
treated cells, but presented in multiple large punctate
structures after treatment with Cl-amidine and doce-
taxel. Though the positive signals were also observed in
Cl-amidine treatment alone, the signal intensity and the
number of positive LC3B puncta were less than the
combined treatment (Fig. 4e). Consistent with LC3B
fluorescence staining, western blotting also showed that
LC3B protein greatly accumulated under the combined
treatment (Fig. 4f). Interestingly, either knockdown
PAD2 or overexpression of miR-125b-5p also promoted
the apoptosis (Additional file 1: Figure S1), induced a
stronger cell cycle arrest in the G2/M phase (Additional
file 1: Figure S2), and enhanced the autophagy (Add-
itional file 1: Figure S3) of the MCF7/TamR cells
treated with 0.1 μM docetaxel. Altogether, these results
suggested a promising nontoxic means by inhibiting
PAD2 with Cl-amidine to enhance the efficacy of
docetaxel.
Cl-amidine combined with docetaxel alters the expression
of genes associated with apoptosis, cell cycle arrest and
autophagy
The effect of combined treatment on cell growth sug-
gested that this drug combination might affect tumor
growth by altering the expression of genes involved in
apoptosis, autophagy, and cell cycle progression. To test
this hypothesis, mRNA from the drug-treated and con-
trol MCF7/TamR cells was examined for the expression
of genes associated with these processes using the RT2
Profiler PCR Array via qRT-PCR. With a threshold value
of 2-fold expression change and a statistical significance
of P < 0.05, the volcano plot shows the top 7-upregulated
and 1-downregulated genes affected by the combined
treatment in comparison to the control cells (Fig. 5a).
Amongst them, GADD45A expression was upregulated
in both the apoptosis and cell cycle arrays, which is con-
sistent with previous studies showing that increased
GADD45A expression leads to cell cycle arrest and
Fig. 5 PCR array analysis of gene expression in cl-amidine combined with docetaxel treatment in MCF7/TamR cells in comparison to control cells.
a Volcano plot human RT2 Profiler PCR Cell for cell apoptosis array, cell cycle array, and autophagy array. The relative expression levels for each
gene depicted as log 2 (n-fold) plotted against –Log10 (P-value). Arrows indicating significantly upregulated or downregulated genes. b qRT-PCR
analysis validated the expression of the genes selected from the PCR arrays in (a). c Gene ontology (GO) function analysis using DAVID
Bioinformatics Resources (http://david.abcc.ncifcrf.gov/) confirming that the genes regulated by the combination treatment were enriched in p53
signaling pathway in cancers (as indicated by arrow)
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apoptosis in a range of cell types, including breast cancer
cells [17, 34]. Similarly, BAX and FAS were present in
both the apoptosis and autophagy arrays, suggesting
cross talk between apoptosis and autophagy induced by
Cl-amidine combined with docetaxel treatment [35, 36].
We then validated the expression of these genes in each
individual treatment and showed that the combined
treatment also significantly increased the expression of
CDKN1A, GADD45A, FAS, BAG3, TNFRSF10B rather
than single agents alone (Fig. 5b). Again, either knock-
down PAD2 or overexpression of miR-125b-5p had the
similar effect as that of PAD2 inhibitor on the expres-
sion of these genes in MCF7/TamR cells treated with
0.1 μM docetaxel (Additional file 1: Figure S4). Import-
antly, gene ontology (GO) function analyses confirmed
that these genes were enriched in p53 signaling pathway
in cancers (Fig. 5c), which is consistent with a previous
report [37], suggesting that the combined treatment may
activate p53, which further regulates p53 target genes.
Cl-amidine combined with docetaxel enhances p53
nuclear accumulation
The transcription activator p53 undergoes nuclear ac-
cumulation in response to several apoptotic stimuli,
plays a central role in the induction of apoptosis, and
thereby mediates cell cycle arrest in cancer cells [38,
39]. To test whether the combined treatment may
also affect p53 nuclear accumulation in MCF7/TamR
cells, we then separated nuclear and cytosolic frac-
tions of the cells and subjected them to western blot-
ting. We found that the cytosolic fraction of p53 was
not affected by either individual drug or the com-
bined treatment, compared to the controls (Fig. 6a).
However, in agreement with the previous reports [38],
docetaxel treatment dramatically induced nuclear p53
levels. Importantly, Cl-amidine activated nuclear p53
accumulation and this accumulation was further en-
hanced by the combined treatment (Fig. 6a). PAD2
knockdown or miR-125b-5p overexpression also pro-
moted nuclear accumulation of p53 in MCF7/TamR
cells treated with 0.1 μM docetaxel (Additional file 1:
Figure S5). To further test the hypothesis that PAD2
regulates p53 nuclear accumulation, we overexpressed
Flag-tagged PAD2 in HEK293 cells and then exam-
ined p53 expression. The results show that PAD2
overexpression does not affect the cytosolic
expression of p53, but decreases nuclear p53 levels
(Fig. 6b). Therefore, inhibiting PAD2 may play an es-
sential role for this synergistic effect on p53 nuclear
accumulation.
PAD2 facilitates p53 degradation by ubiquitination
The molecular mechanism for how PAD2 regulates p53
is currently unknown. Given that p53 degradation,
Fig. 6 Inhibiting PAD2 combined with docetaxel treatment promoted nuclear accumulation of p53 in MCF7/TamR cells, and PAD2 facilitates p53
degradation by ubiquitination. a Cellular proteins after 0.1 μM docetaxel and 25 μM cl-amidine treatment were separated into cytoplasmic and
nuclear pools by fractionation methods and examined by western blot with anti-p53 antibody. Cleanliness of fractionation was determined by
probing with antibodies for Histone H3 (nuclear) and GAPDH (cytoplasmic) proteins. b HEK293 cells were transfected with Flag-tagged PAD2
followed by cellular fractionation analysis. Western blotting showing that cellular p53 expression was not affected by PAD2 overexpression, but
nuclear p53 expression decreased. c HEK293 cells were transfected with HA-tagged ubiquitin (HA-Ub) and Flag-tagged PAD2, followed by
immunoprecipitation assay by anti-p53 antibody. The immunoprecipitates were detected by anti-HA antibody. GAPDH served as loading control
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mediated by the E3 ubiquitin ligase Mdm2, is gener-
ally accepted as the major mechanism of p53 regula-
tion [40, 41], we determined whether PAD2 may
influence p53 ubiquitination. In that case, inhibiting
PAD2 would be expected to prevent p53 degradation,
which could explain the greatly promoted effect of
Cl-amidine on p53 stability as observed in Fig. 6a. To
test this hypothesis, we performed a ubiquitination
assay (Fig. 6c). HA-tagged ubiquitin (HA-Ub) with
both the presence and absence of Flag-tagged PAD2
were transfected into 293 cells and p53 was immuno-
precipitated with an anti-p53 antibody. The ubiquiti-
nation status of p53 was determined by western
blotting using an anti-HA antibody. Expression of
PAD2 dramatically increased the ubiquitination of
p53, suggesting that PAD2 facilitates p53 degradation
by ubiquitination.
Cl-amidine combined with docetaxel synergistically
decreases the activation of Akt/mTOR signaling
Accumulating studies have shown that p53 inhibits the
mammalian target of rapamycin (mTOR) signaling path-
way in response to cellular stresses [42, 43]. Wang et al.
showed that inhibition of PAD4, another PAD family
member, with inhibitor YW3–56, activates a cohort of
p53 target genes, which in turn inhibits the mTORC1
signaling pathway, thereby perturbing autophagy and
inhibiting cancerous cell growth [44]. Hence, we sought
to determine whether Cl-amidine and docetaxel treat-
ment also suppress Akt/mTOR signaling. To do this, we
first showed that the levels of phosphorylated Akt and
Rps6 were decreased in MCF7/TamR cells treated with
either docetaxel or Cl-amidine, whereas a combination
of docetaxel and Cl-amidine nearly completely inhibited
Akt and Rps6 phosphorylation (Fig. 7a). PAD2
Fig. 7 Cl-amidine combined with docetaxel synergistically decreases the activation of Akt/mTOR signaling. a Western blot analysis showing that
the levels of p-Akt and p-Rps6 were decreased in MCF7/TamR cells treated with either docetaxel or cl-amidine, whereas a combination of
docetaxel and cl-amidine nearly completely inhibited Akt and Rps6 phosphoryaltion. Total Akt and Rps6 proteins were not affected. GAPDH
served as loading control. b MCF7/TamR cells were treated with 10 μM MHY1485, followed by cl-amidine and docetaxel treatment. Western blot
analysis showing that pretreatment of cells with MHY1485 fully abolished the inhibitory effect of cl-amidine combined with docetaxel on Rps6
activation. GAPDH served as loading control. c MCF7/TamR cells were treated with 10 μM MHY1485, followed by cl-amidine and docetaxel
treatment. CCK8 assay showing passively activating mTOR by MHY1485 reversed the inhibiting effect on viability of MCF7/TamR cells caused by
cl-amidine and docetaxel combination treatment. (*P < 0.05). d MCF7/TamR cells were inoculated into the nude mice. Two weeks later, the mice
were randomly divided into 4 groups and received PBS control, docetaxel, cl-amidine, or the combination injection (n = 6/group). The tumors
were removed and the tumor weight was then recorded and plotted. *P < 0.05. e Western blot analysis of the mouse xenograft tumors with the
antibodies against Bak, PCNA, p-Akt, Akt, p-Rps6, Rps6, and GAPDH
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knockdown or miR-125b-5p overexpression also further
decreased the levels of phosphorylated Akt and Rps6
phosphorylation in MCF7/TamR cells treated with
0.1 μM docetaxel (Additional file 1: Figure S6). Next, we
treated MCF7/TamR cells with 10 μM MHY1485, a
small-molecular mTOR activator, followed by Cl-
amidine and docetaxel treatment. The results showed that
pretreatment of cells with MHY1485 fully abolished the in-
hibitory effect of Cl-amidine combined with docetaxel on
Rps6 activation (Fig. 7b). Furthermore, pretreatment of
PAD2 knockdown or miR-125b-5p overexpression MCF7/
TamR cells with MHY1485 also abolished the inhibitory ef-
fect of docetaxel on Rps6 activation (Additional file 1: Figure
S7). Additionally, passively activating mTOR by MHY1485
also reversed the inhibiting effect on viability of MCF7/
TamR cells caused by Cl-amidine and docetaxel treatment
(Fig. 7c), as well as PAD2 knockdown or miR-125b-5p over-
expression MCF7/TamR cells (Additional file 1: Figure S8).
Furthermore, we tested the synergy of the PAD2 inhibitor
and docetaxel in tumor growth in vivo (n= 6). We found
that after injection of a mix of Cl-amidine and docetaxel, the
tumor weight significantly decreased compared to that of
each single treatment (Fig. 7d). As expected, the combined
treatment also upregulated the expression of pro-apoptotic
protein Bak and decreased the expression of cell proliferation
marker PCNA in tumor tissues (Fig. 7e), indicating an addi-
tive effect of the two inhibitors. Correspondingly, the activa-
tion of Akt and Rps6 was strikingly inhibited after the
combined treatment in the mouse xenograft tumors (Fig. 7e).
Together, these results suggested that Cl-amidine and doce-
taxel may target upstream regulators for mTOR signaling,
which help inhibit MCF7/TamR tumors.
Discussion
Tamoxifen resistance in breast cancer therapy presents a
huge clinical challenge [3, 4]. More detailed molecular
mechanisms relevant to tamoxifen resistance and new
therapy regimens benefit the breast cancer patients [45].
In our study, we first demonstrate that PAD2 is required
for tamoxifen resistance in breast cancers and may rep-
resent a novel therapeutic target for tamoxifen resistance
in breast cancers. Importantly, our study showing that
PAD2 inhibition with Cl-amidine can partially restore
the sensitivity of TamR/MCF7 cells to tamoxifen sug-
gests that Cl-amidine may represent a new candidate for
breast cancer therapy. Previous studies have shown that
Cl-amidine causes cancer cell growth inhibition at 150–
200 μM concentration in several breast cancer cell lines,
while it does not affect the growth of the non-
tumorigenic cells and was well tolerated by mice [17, 30,
46, 47]. Moreover, Cl-amidine combination with doxo-
rubicin or the HDAC inhibitor SAHA can have synergis-
tic cytotoxic effects on cells [31, 46–48]. In agreement
with these reports, our study shows that combination
treatment with 50 μM Cl-amidine and 5 μM tamoxifen ex-
hibit a much stronger antiproliferative effect as compared
to all individual treatments, though this inhibitory effect
was not complete. To achieve better results, we applied a
combination of 25 μM Cl-amidine and 0.1 μM docetaxel.
This combined treatment nearly completely inhibited
MCF7/TamR cells. To our knowledge, this is the lowest
concentration of Cl-amidine (6–8-fold lower than the regu-
lar dosage used in treating cancer cells) reported so far to
have such a significant inhibitory effect on cancer cells. In
addition, this drug regimen also decreased docetaxel dosage
from 80 μM when used alone to 0.1 μM when used in com-
bination. The synergy of the PAD2 inhibitor and docetaxel
was also confirmed in tumor growth in vivo. High-dose do-
cetaxel therapy was found to be associated with safety is-
sues among clinical trial patients and effective strategies to
decrease the dosage are urgently needed [5, 10]. Therefore,
our drug regimen may provide a better therapeutic strategy
to reduce the dose of docetaxel used for those patients with
tamoxifen-resistant breast cancer in the future.
p53 plays a pivotal role in controlling cell-cycle pro-
gression and apoptosis [40]. It has been shown that
PAD2 is involved in regulating the expression of both
cell cycle and tumor promoting genes [17] and inhibiting
PAD2 with Cl-amidine effectively upregulates several
p53-regulated genes, leading to an increase in apoptosis
and cell cycle arrest [47, 48]. Meanwhile, docetaxel can
upregulate p53 expression, and treatment of breast
cancer cells with docetaxel induces a sustained arrest
in mitosis with the consequent inhibition of transcrip-
tion and higher p53 accumulation followed by apop-
tosis [32]. In agreement with these findings, our study
showed synergism between Cl-amidine and docetaxel
in enhancing the activation of p53, and that the com-
bination treatment synergistically induced apoptosis
and cell cycle arrest in the G2/M phase (Fig. 8).
Regarding the molecular mechanism of the additive
effect, we showed that PAD2 promotes p53 ubiquiti-
nation and its subsequent degradation. Inhibiting
PAD2 reversed p53 degradation, leading to enhanced
p53 nuclear accumulation with docetaxel co-
treatment. Of note, the combination treatment also
induced autophagy in MCF7/TamR cells. Autophagy
exhibits either a protumorigenic or antitumorigenic
function, depending on the cell type, developmental
stage of cancer and stimulator [49]. Wang and col-
leagues have shown that PAD inhibitors activate p53,
which in turn inhibits the mTOR signaling pathway,
and induces autophagy and cancer growth inhibition
[23, 25, 45]. Docetaxel has also been reported to in-
duce breast cancer cell autophagy [42]. Given that
both Cl-amidine and docetaxel can activate p53, the
combination treatment in our study may accelerate
the autophagy processes by synergistically inhibiting
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Akt/mTOR signing, thus leading to the enhanced pro-
liferation inhibition.
In our study, we only used cell line-derived xenograft
mouse models and could not use patient-derived xeno-
grafts, since it is difficult to obtain patient-derived ER-
positive xenografts. We will test our hypothesis in
patient-derived ER-positive xenografts in our future
studies once the samples are available. We hope that
with this model, we will provide more predictive values
for clinical outcomes. Additionally, to our knowledge,
tamoxifen is still the first-line endocrine therapy for pre-
menopausal, ER positive metastatic breast cancer in
China, while fulvestrant as ER antagonis, is usually pre-
ferred in postmenopausal women with advanced breast
cancer [50]. It is currently unknown whether PAD2 is
also involved in fulvestrant resistance breast cancer or
not. Clearly, the role of PAD2 in fulvestrant resistance
breast cancer still needs to be determined.
Conclusions
We provided here an important new line of evidence dem-
onstrating that PAD2 was highly expressed in tamoxifen-
resistant breast cancer, raising a possibility that upregulated
PAD2 may be involved in tamoxifen-resistance in breast can-
cer. Treatment with PADs inhibitor can partially resensitize
TamR/MCF7 cells to tamoxifen. Most importantly, we dem-
onstrated a synergistic and effective drug regimen of PADs
inhibitor and docetaxel (with lower concentrations of both
drugs) on tamoxifen-resistant breast cancer cells. Such com-
bination therapy may be a novel potential therapeutic ap-
proach for patients with this form of breast cancer.
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Additional file 1: Figure S1. Flow cytometric analysis of PAD2
knockdown (a) or miR-125b-5p overexpression (b) accelerated apoptosis
of the MCF7/TamR cells treated with 0.1 μM docetaxel. Relative apoptosis
ratio is quantified on the right. shCon: shRNA control MCF7/TamR cells;
shPAD2: PAD2 knockdown cells; EV con: Empty vector pQXCIP
overexpression MCF7/TamR cells; miR-125b-5p: miR-125b-5p
overexpression; Doc: docetaxel; PBS was used as a control.
Additional file 2: Figure S2. Flow cytometric analysis of PAD2
knockdown (a) or miR-125b-5p overexpression (b) induced a stronger cell
cycle arrest in the G2/M phase of the MCF7/TamR cells treated with 0.1
μM docetaxel. The relative quantification was shown below the
representative images. shCon: shRNA control MCF7/TamR cells; shPAD2:
PAD2 knockdown cells; EV con: Empty vector pQXCIP overexpression
MCF7/TamR cells; miR-125b-5p: miR-125b-5p overexpression; Doc:
docetaxel; PBS was used as a control. (*P < 0.05).
Additional file 3: Figure S3. Western blot analysis of the PAD2
knockdown (a) or miR-125b-5p overexpression (b) accumulated LC3B
protein expression in the MCF7/TamR cells treated with 0.1 μM docetaxel.
shCon: shRNA control MCF7/TamR cells; shPAD2: PAD2 knockdown cells;
EV con: Empty vector pQXCIP overexpression MCF7/TamR cells; miR-
125b-5p: miR-125b-5p overexpression; Doc: docetaxel; PBS was used as a
control. GAPDH served as loading control.
Additional file 4: Figure S4. qRT-PCR analysis showing that PAD2
knockdown (a) or miR-125b-5p overexpression (b) significantly increased
the expression of CDKN1A, GADD45A, FAS, BAG3, TNFRSF10B in the
MCF7/TamR cells treated with 0.1 μM docetaxel. shCon: shRNA control
MCF7/TamR cells; shPAD2: PAD2 knockdown cells; EV con: Empty vector
pQXCIP overexpression MCF7/TamR cells; miR-125b-5p: miR-125b-5p
overexpression; Doc: docetaxel; PBS was used as a control. Gene
expression normalized to GAPDH. (*P < 0.05).
Additional file 5. Figure S5. Western blot analysis of the PAD2 knockdown
(a) or miR-125b-5p overexpression (b) promoted nuclear accumulation of p53
in MCF7/TamR cells treated with 0.1 μM docetaxel. Cellular proteins after 0.1
μM docetaxel treatment were separated into cytoplasmic and nuclear pools
by fractionation methods and examined by western blot with anti-p53
antibody. Cleanliness of fractionation was determined by probing with
antibodies for Pol II (nuclear) and GAPDH (cytoplasmic) proteins. shCon:
shRNA control MCF7/TamR cells; shPAD2: PAD2 knockdown cells; EV con:
Empty vector pQXCIP overexpression MCF7/TamR cells; miR-125b-5p: miR-
125b-5p overexpression; Doc: docetaxel; PBS was used as a control.
Additional file 6. Figure S6. Western blot analysis of the PAD2 knockdown
(a) or miR-125b-5p overexpression (b) further decreased the levels of
phosphorylated Akt and Rps6 phosphorylation in MCF7/TamR cells treated
with 0.1 μM docetaxel. GAPDH served as loading control. shCon: shRNA
control MCF7/TamR cells; shPAD2: PAD2 knockdown cells; EV con: Empty
vector pQXCIP overexpression MCF7/TamR cells; miR-125b-5p: miR-125b-5p
overexpression; Doc: docetaxel; PBS was used as a control.
Fig. 8 Schematic of the synergistic effects of cl-amidine and
docetaxel on p53/Akt/mTOR signaling in regulation of genes
associated with cell apoptosis, cell cycle arrest and autophagy.
Inhibiting PAD2 reverses p53 degradation, leading to the enhanced
p53 nuclear accumulation with docetaxel co-treatment, thus
accelerating cell apoptosis and cell cycle arrest. The combination
treatment also promotes the autophagy processes by synergistically
inhibiting Akt/mTOR signing, leading to the enhanced
proliferation inhibition
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Additional file 7. Figure S7. Western blot analysis showing that
pretreatment of PAD2 knockdown (a) or miR-125b-5p overexpression (b)
MCF7/TamR cells with 10 μM MHY1485 abolished the inhibitory effect of
docetaxel on Rps6 activation. GAPDH served as loading control; shPAD2:
PAD2 knockdown MCF7/TamR cells; miR-125b-5p: miR-125b-5p
overexpression MCF7/TamR cells; Doc: docetaxel; PBS was used as a control.
Additional file 8. Figure S8. CCK8 assay showing passively activating mTOR
by MHY1485 reversed the inhibiting effect of docetaxel on viability of PAD2
knockdown (a) or miR-125b-5p overexpression (b) MCF7/TamR cells. shCon:
shRNA control MCF7/TamR cells; shPAD2: PAD2 knockdown cells; EV con: Empty
vector pQXCIP overexpression MCF7/TamR cells; miR-125b-5p: miR-125b-5p
overexpression cells; Doc: docetaxel; PBS was used as a control. (*P < 0.05).
Additional file 9: Table S1. qRT-PCR primer sequences used in the study.
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